Genomic Basis of Neurodevelopmental and Brain Outcomes in Congenital Heart Disease (CHD Brain and Genes)

Completed

Conditions studied: Heart Disease Congenital

In brief

Approximately 400 Congenital heart disease patients will participate in the research study which will include one or more research visits for neurodevelopmental testing, brain MRI, and collection of medical history including previously collected genetic sequencing results. The investigators will explore the association between genetic variants, neurodevelopmental deficits, and brain MRI endophenotype. Analyses will compare groups with and without deleterious de novo mutations.

Key facts

Study ID

NCT03070197

Run by

Children's Hospital Medical Center, Cincinnati

People needed

196

Starts

2017-09-18

Expected to finish

2020-06-29

Last updated by the study team

2020-08-13

Who can join

Age: 8 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects in whom whole exome sequencing or whole genome sequencing has already been performed, either during the CHD GENES study or, for new centers (Utah or USCF/Stanford), after trios in existing biobanks undergo analysis by whole exome sequencing or whole genome sequencing during the Pediatric Cardiac Genomic Consortium 2 grant cycle
• Presence of deleterious mutations (damaging de novo mutations or stringently defined deleterious missense mutations) identified on sequencing (Cases) OR absence of such known deleterious mutations (Controls)
• Males or females, age ≥8 years
• Diagnosis of congenital heart disease
• Informed consent obtained

You may not qualify if…

• History of cardiac transplant
• A cardiac surgical procedure within 6 months of enrollment
• Known clinical genetic syndrome, characterized as a monogenic condition with an identified gene associated with abnormalities of the brain structure or function, structural heart disease, and potentially other associated features.
• Presence of CNV known to be clinically pathogenic. Variants will be classified as pathogenic using accepted types of variant evidence (e.g., population data, computational data, functional data, segregation data) as detailed in the American College of Medical Genetics and Genomics " Standards and Guidelines for the interpretation of sequence variants" (Richards et al, GIM 2015).
• Overwhelming acquired brain injury, such as a major stroke or severe ischemic injury, that would overshadow the effect of a genetic mutation on outcome in the opinion of the center investigator
• Lack of reading fluency in English or Spanish

Where it is running

• Children's Hospital Los Angeles — Los Angeles, California, United States
• University of California, San Francisco — San Francisco, California, United States
• Yale University — New Haven, Connecticut, United States
• Children's Hospital Boston — Boston, Massachusetts, United States
• Icahn School of Medicine at Mt. Sinai — New York, New York, United States
• University of Rochester — Rochester, New York, United States
• Children's Hospital Philadelphia — Philadelphia, Pennsylvania, United States
• University of Utah — Salt Lake City, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.